Sunterra Biotech

Sunterra Biotech is a clinical-stage biotechnology company focused on developing next-generation therapies for metabolic and endocrine diseases. The company's lead program, ST-002, is a long-acting Fibroblast Growth Factor 21 (FGF21) analog designed to improve metabolic health with a potentially superior dosing profile and efficacy compared to existing treatments. Sunterra leverages its proprietary protein engineering platform to create optimized biologics that address significant unmet needs in conditions such as MASH, obesity, and type 2 diabetes. Headquartered in San Diego, the company is advancing its pipeline through early-stage clinical trials to validate its metabolic-regulating approach.